June 2016
Intermediate to advanced
264 pages
5h 51m
English
Here we take a look at what happened next to the main characters and companies involved in the campaigns chronicled in this book.
Bill Ackman: Though his relationship with Valeant’s Michael Pearson failed to bring about their initial aim of buying Allergan, the two continued to work closely together and Pershing became a significant investor in Valeant. But the relationship between the two was put under considerable strain, especially when serious problems emerged at the drug maker throughout 2015. Ackman joined the Valeant board in spring 2016 as the situation worsened.
Allergan: After having been taken over by Activis, the new company renamed itself Allergan PLC and relocated to Ireland, where Activis had been ...
Read now
Unlock full access